基本信息
浏览量:42
职业迁徙
个人简介
Major research interest of Dr. Tanaka is regarding tumor angiogenesis, one of the pivotal pathogenesis of malignant tumors including glioblastoma and therapeutic targets. In the field of basic science, he developed animal models for therapeutics utilizing viral vectors carrying antiangiogenic genes including platelet factor 4, angiostatin, and endostatin.
In the field of neuro-oncology, the innovative work of Dr. Tanaka’s multidisciplinary team has focused on the design and selection of personalized hypervascular malignant glioma treatments based on neuroradiological findings by preoperative administratin of bevacizumab, demonstrating a benefit of surgical radical resection for which hyper-vascular tumor turning into less vascular and decreasing tumor volume and edema. Comparative in situ histological investigation between with or without bevacizumab demonstrated that tumor oxygenation and diminishing of cancer stem cells were induced during effectiveness of bevacizumab, compared with tumors in naïve or recurrence after bevacizumab therapy. In addition, he demonstrated that bevacizumab has an additional benefit for providing immunosupportive tumor microenvironment, which was induced by inhibition of immunosuppressive cells including regulatory T cells and M2-polarized tumor associated macrophages, and immune checkpoint molecules including PD-1 and PD-L1. Those alterations caused induction of cytotoxic T cells, which might accelerate the effectiveness of tumor immunotherapy.
In the field of neuro-oncology, the innovative work of Dr. Tanaka’s multidisciplinary team has focused on the design and selection of personalized hypervascular malignant glioma treatments based on neuroradiological findings by preoperative administratin of bevacizumab, demonstrating a benefit of surgical radical resection for which hyper-vascular tumor turning into less vascular and decreasing tumor volume and edema. Comparative in situ histological investigation between with or without bevacizumab demonstrated that tumor oxygenation and diminishing of cancer stem cells were induced during effectiveness of bevacizumab, compared with tumors in naïve or recurrence after bevacizumab therapy. In addition, he demonstrated that bevacizumab has an additional benefit for providing immunosupportive tumor microenvironment, which was induced by inhibition of immunosuppressive cells including regulatory T cells and M2-polarized tumor associated macrophages, and immune checkpoint molecules including PD-1 and PD-L1. Those alterations caused induction of cytotoxic T cells, which might accelerate the effectiveness of tumor immunotherapy.
研究兴趣
论文共 142 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Journal of Neuro-Oncologyno. 3 (2024): 557-567
Taketo Ezaki,Toshihide Tanaka,Ryota Tamura, Kentaro Ohara,Yohei Yamamoto,Jun Takei,Yukina Morimoto,Ryotaro Imai, Yuki Kuranari, Yasuharu Akasaki,Masahiro Toda,Yuichi Murayama,
NEURORADIOLOGY JOURNALpp.19714009241242657-19714009241242657, (2024)
CANCER SCIENCE (2023): 1008-1008
引用0浏览0引用
0
0
INTERVENTIONAL NEURORADIOLOGYpp.15910199231189927-15910199231189927, (2023)
AJNR. American journal of neuroradiology (2023)
引用0浏览0WOS引用
0
0
Interventional Neuroradiology (2023)
引用0浏览0引用
0
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn